Catalent Pharma Solutions is expanding its inhalation drug development, delivery and supply capabilities at its Inhalation Center of Excellence in Research Triangle Park (RTP), NC. The $20 million investment will focus on expanding pressurized Metered Dose Inhaler (pMDI) clinical and commercial supply capabilities.
Catalent provides a broad range of inhalation services including API optimization, pre-formulation, formulation, analytical testing and manufacturing across all inhaled dosage forms at the RTP facility.
“Pulmonary and nasal represents the second largest drug delivery market by delivery route. Catalent’s investment in commercial manufacturing at our Inhalation Center of Excellence not only fits with our advanced drug delivery growth strategy, but also positions us as a world leader supporting inhaled products,” said Scott Houlton, president of Catalent’s Development and Clinical Services business.
“In addition to the introduction of scalable processes for micro-dosing inhalation powder formulations, and the recent commissioning of our new nasal filling suite, this $20 million investment will upgrade our pMDI manufacturing capacity and allow us to better support our customers from early development all the way through to commercialization; bringing more products and better treatments to market faster,” Mr. Houlton added.